Skip to content
PreclinicalResearch compoundReference only

Dimiracetam

Experimental racetam-related compound for nerve (neuropathic) pain; worked in animal studies, not proven in humans.

NootropicRacetamRacetamGlutamateGlutamateNMDA

Pharmacology

ClassRacetam · Glutamate
Primary targetNMDA-linked glutamate release normalizer
Targets4 receptor targets
Half-lifeN/A (short plasma half-life; the effect substantially outlasts it)
OnsetN/A (not characterized for general use; study protocols varied)
EvidenceReference only
Affected systemsGlutamateNMDA

Contents

DETAILED OVERVIEW

What is Dimiracetam?

Dimiracetam is an experimental compound related to the racetams. It was originally developed to improve thinking, but was later studied mainly in long-lasting pain linked to nerve injury, chemotherapy or joint wear. It is not an approved medicine; in Australia it is classed as prescription-only.

In the spinal cord it reduces the excessive release of glutamate, a messenger substance that excites nerve cells, which dampens pain signaling. In animal studies it durably reduced pain hypersensitivity, and the effect persisted after the compound had left the body. So far it has been studied mainly in animals and is not proven in humans: although it reached early clinical trials, the results are not available. There is no detailed human side-effect data, so effects such as dizziness or headache cannot be ruled out. There is no safety data for pregnancy and breastfeeding.

Mechanism

Reduces NMDA-linked glutamate release

Evidence

Mostly preclinical (animal models)

Legal status

Investigational; AU: prescription-only

Receptor profile

  • NMDA receptors (GluN1 / GluN2A)Moderate
  • Glutamatergic signalingModerate
  • Neuropathic pain pathwaysModerate
  • Learning / memory circuitsWeak

Safety

Side effects, stop signs, contraindications

Side effects · 4

  • Described as well tolerated in animal studies; human safety is not fully established
  • A detailed human side-effect profile is not published in the public literature
  • As an NMDA-glutamatergic modulator, dose-dependent central nervous system effects (e.g. dizziness, headache) cannot be theoretically excluded
  • No long-term human safety data are available

Contraindications · 4

  • Pregnancy and breastfeeding: no safety data, should be avoided
  • Hepatic or renal impairment: no human pharmacokinetic data, caution / medical supervision
  • Investigational compound: not approved for self-medication outside a clinical trial
  • Prescription-only in Australia (Schedule 4): a legal restriction applies

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Dimiracetam is a racetam-related research compound originally described as a cognition-supporting agent, but later studied mainly for chronic pain linked to nerve injury, chemotherapy, or joint wear. The evidence so far is mostly from animal studies, which showed lasting pain-relieving effects even at reduced doses, but solid human, clinical-level evidence is still largely lacking.

Telegram

Have a question about Dimiracetam?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC6H8N2O2
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.